Anti-PSMA chimeric antigen receptor tumour cell therapy - TNK TherapeuticsAlternative Names: CAR-T PSMA; Prostate specific membrane antigen inhibitor - TNK Therapeutics; PSMA CART
Latest Information Update: 13 Nov 2015
At a glance
- Originator BDL Products, Inc.; CARgenix Holdings LLC
- Developer TNK Therapeutics
- Class CAR-T cell therapies
- Mechanism of Action Glutamate carboxypeptidase II inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer